Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Goodwill Amortization of Goodwill Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Discontinued Operations Cash from Discontinued Operations Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Avanos Medical (AVNS) Asset Writedowns and Impairment (2024)

Avanos Medical's Asset Writedowns and Impairment history spans 1 years, with the latest figure at $336.5 million for Q4 2024.

On a quarterly basis, Asset Writedowns and Impairment changed N/A to $336.5 million in Q4 2024 year-over-year; TTM through Dec 2024 was $336.5 million, a N/A change, with the full-year FY2025 number at $77.0 million, down 82.37% from a year prior.
Asset Writedowns and Impairment hit $336.5 million in Q4 2024 for Avanos Medical.
Over the last five years, Asset Writedowns and Impairment for AVNS hit a ceiling of $336.5 million in Q4 2024 and a floor of $336.5 million in Q4 2024.